Moderna Inc (MRNA)vsNewcelX Ltd. (NCEL)
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
NCEL
NewcelX Ltd.
$2.70
-1.46%
HEALTHCARE · Cap: $14.44M
Smart Verdict
WallStSmart Research — data-driven comparison
NCEL leads profitability with a 0.0% profit margin vs -141.4%. NCEL earns a higher WallStSmart Score of 22/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NCEL
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Intrinsic value data unavailable for NCEL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NCEL
The strongest argument for NCEL centers on P/E Ratio, Debt/Equity, Price/Book.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NCEL
The primary concerns for NCEL are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NCEL is a value play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NCEL generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
NCEL scores higher overall (22/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
NewcelX Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?